Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Denali Therapeutics Inc. | Director | Common Stock | 9.67M | $178M | $18.42 | Jun 2, 2021 | Held by ARCH Venture Fund VIII, L.P. |
Sana Biotechnology, Inc. | Director, 10%+ Owner | Common Stock | 12.4M | $68.5M | $5.50 | Feb 8, 2024 | Indirect |
Lyell Immunopharma, Inc. | Director, 10%+ Owner | Common Stock | 18.2M | $41.5M | $2.28 | Jun 14, 2024 | ARCH Venture Fund IX,L.P. |
Lyell Immunopharma, Inc. | Director, 10%+ Owner | Common Stock | 18.2M | $41.5M | $2.28 | Jun 14, 2024 | ARCH Venture Fund IX Overage, L.P. |
Prime Medicine, Inc. | Director, 10%+ Owner | Common Stock | 6.13M | $38.3M | $6.25 | Feb 15, 2024 | By ARCH Venture Fund X, L.P. |
Prime Medicine, Inc. | Director, 10%+ Owner | Common Stock | 6.13M | $38.3M | $6.25 | Feb 15, 2024 | By ARCH Venture Fund X Overage, L.P. |
Prime Medicine, Inc. | Director, 10%+ Owner | Common Stock | 3.2M | $20M | $6.25 | Feb 15, 2024 | By ARCH Venture Fund XII, L.P. |
Vir Biotechnology, Inc. | Director | Common Stock | 584K | $5.52M | $9.46 | May 30, 2024 | Direct |
Vir Biotechnology, Inc. | Director | Common Stock | 33.9K | $321K | $9.46 | May 30, 2024 | Indirect |
Denali Therapeutics Inc. | Director | Common Stock | 12.4K | $229K | $18.42 | Jun 2, 2021 | Direct |
Prime Medicine, Inc. | Director, 10%+ Owner | Common Stock | 16.1K | $101K | $6.25 | Feb 15, 2024 | Indirect |
Vir Biotechnology, Inc. | Director | Stock Option (Right to Buy) | 16K | $24.5K | $1.53 | May 30, 2024 | Direct |
Sana Biotechnology, Inc. | Director, 10%+ Owner | Common Stock | 1.35K | $7.44K | $5.50 | Feb 8, 2024 | Direct |
Lyell Immunopharma, Inc. | Director, 10%+ Owner | Option (right to buy) | 130K | Jun 14, 2024 | Direct | ||
Sana Biotechnology, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 65K | Jun 6, 2024 | Direct | ||
Prime Medicine, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 45K | Jun 12, 2024 | Direct | ||
Denali Therapeutics Inc. | Director | Stock Option (right to buy) | 6.22K | Jun 2, 2021 | Direct | ||
Denali Therapeutics Inc. | Director | Restricted Stock Units | 0 | Jun 1, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LYEL | Lyell Immunopharma, Inc. | Jun 14, 2024 | 1 | $0 | 4 | Jun 17, 2024 | Director, 10%+ Owner |
PRME | Prime Medicine, Inc. | Jun 12, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jun 6, 2024 | 1 | $0 | 4/A | Jul 15, 2024 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | May 30, 2024 | 2 | $0 | 4 | Jun 3, 2024 | Director |
PRME | Prime Medicine, Inc. | Feb 15, 2024 | 1 | $20M | 4 | Feb 20, 2024 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Feb 8, 2024 | 3 | $10M | 4 | Feb 12, 2024 | Director, 10%+ Owner |
LYEL | Lyell Immunopharma, Inc. | Sep 8, 2023 | 1 | $0 | 4 | Sep 8, 2023 | Director, 10%+ Owner |
LYEL | Lyell Immunopharma, Inc. | Jun 16, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director, 10%+ Owner |
PRME | Prime Medicine, Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 12, 2023 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | May 22, 2023 | 2 | $0 | 4 | May 24, 2023 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jan 5, 2023 | 1 | $0 | 4 | Jan 6, 2023 | Director, 10%+ Owner |
PRME | Prime Medicine, Inc. | Oct 24, 2022 | 10 | $13.6M | 4 | Oct 26, 2022 | Director, 10%+ Owner |
PRME | Prime Medicine, Inc. | Oct 19, 2022 | 0 | $0 | 3/A | Oct 24, 2022 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Oct 5, 2022 | 1 | $0 | 4 | Oct 6, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Sep 2, 2022 | 8 | $0 | 4 | Sep 7, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Aug 30, 2022 | 8 | $0 | 4 | Sep 1, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Aug 24, 2022 | 8 | $0 | 4 | Aug 26, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Aug 18, 2022 | 4 | $0 | 4 | Aug 22, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Aug 12, 2022 | 12 | $0 | 4 | Aug 16, 2022 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jul 5, 2022 | 1 | $0 | 4 | Jul 7, 2022 | Director |
VIR | Vir Biotechnology, Inc. | Jun 8, 2022 | 4 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
LYEL | Lyell Immunopharma, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Jun 6, 2022 | 1 | $0 | 4 | Jun 8, 2022 | Director |
VIR | Vir Biotechnology, Inc. | Jun 2, 2022 | 3 | $0 | 4 | Jun 6, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | May 23, 2022 | 2 | $0 | 4 | May 25, 2022 | Director, 10%+ Owner |
SANA | Sana Biotechnology, Inc. | Apr 5, 2022 | 1 | $0 | 4 | Apr 6, 2022 | Director |
VIR | Vir Biotechnology, Inc. | Dec 20, 2021 | 1 | $0 | 4/A | May 10, 2022 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Nov 29, 2021 | 3 | $0 | 4 | Dec 1, 2021 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Nov 22, 2021 | 3 | $0 | 4 | Nov 24, 2021 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Jul 1, 2021 | 3 | $0 | 4 | Jul 6, 2021 | Director, 10%+ Owner |
VIR | Vir Biotechnology, Inc. | Jun 22, 2021 | 3 | $0 | 4 | Jun 24, 2021 | Director, 10%+ Owner |
LYEL | Lyell Immunopharma, Inc. | Jun 21, 2021 | 6 | $0 | 4 | Jun 23, 2021 | Director, 10%+ Owner |
LYEL | Lyell Immunopharma, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | Director, 10%+ Owner |
DNLI | Denali Therapeutics Inc. | Jun 2, 2021 | 2 | $0 | 4 | Jun 4, 2021 | Director |
VIR | Vir Biotechnology, Inc. | May 21, 2021 | 2 | $0 | 4 | May 25, 2021 | Director, 10%+ Owner |
DNLI | Denali Therapeutics Inc. | Mar 22, 2021 | 6 | $0 | 4 | Jun 3, 2021 | Director |